A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease
Last Updated: Monday, May 16, 2022
A phase 1 trial demonstrated for the first time that infusing polyclonal healthy donor regulatory T cells followed by expansion with low-dose interleukin-2 is safe in patients with steroid-refractory chronic GvHD.
Advertisement
News & Literature Highlights